Banca Monte dei Paschi di Siena (OTCPK:BMDP.F) Update / briefing February 27, 2026 03:00 AM ET Speaker9Good morning. This is the Chorus Call Conference operator. Welcome, and thank you for joining the MPS Business Plan 2026, 2030 presentation. As a reminder, all participants are in listen-only mode. After the presentation, there will be an opportunity to ask questions. Should anyone need assistance during the conference call, they may signal an operator by pressing star and zero on their telephone. At this ...

Summary of Everpure (NYSE:PSTG) FY Conference Call - February 26, 2026 Company Overview - **Company Name Change**: Pure Storage has rebranded to Everpure to reflect its expanded capabilities in the enterprise storage industry [11][14] - **Acquisition**: The company acquired 1touch to enhance its data management capabilities, allowing for better context and usability of stored data [13][19] Financial Performance - **Quarterly Earnings**: Everpure reported its first billion-dollar quarter with revenues of approximately $1.06 billion, marking a 16% year-over-year growth for the full year and a 20% growth in Q4 compared to the previous year [15][16] - **Future Guidance**: The company anticipates a 28% growth in Q1 year-over-year and a 19% growth for the entire year [15][16] - **Competitor Comparison**: Competitors are experiencing low single-digit growth rates, indicating Everpure's strong market position [16] Industry Dynamics - **NAND Flash Supply Chain**: Everpure has begun selling to hyperscalers, significantly increasing its responsibility for NAND flash supply. The company has long-term contracts in place but acknowledges the volatility in the spot market due to high demand and supply shortages [22][23][24] - **NAND Pricing**: The company noted that NAND prices have seen dramatic increases, with some products doubling in price within four months [23][24][90][96] - **Transition from HDD to Flash**: Everpure predicts that by 2028, virtually no new HDD enterprise data center systems will be sold, despite HDDs currently representing around 80% of gigabytes in hyperscalers [45][60] Competitive Positioning - **DirectFlash Technology**: Everpure's DirectFlash technology offers a 30%-40% price performance improvement over traditional SSDs, positioning the company uniquely in the market [66][67] - **Power and Cooling Efficiency**: Everpure's solutions require significantly less power, space, and cooling compared to HDDs and SSDs, making them attractive to hyperscalers [67][71] Market Trends - **AI and Data Management**: The company is focusing on making data more manageable and useful for analytics and AI, addressing the need for real-time data processing [135][136] - **Hyperscaler Demand**: Hyperscalers are currently price insensitive due to their urgent need for capacity, which is driving demand for Everpure's solutions [116][117] Strategic Partnerships - **Nutanix Partnership**: Everpure is seeing increased demand for alternatives to VMware, with Nutanix being a key partner in providing solutions for customers looking to transition away from VMware [172][173] Key Takeaways - **Market Share Growth**: Everpure is experiencing significant growth in its core business, with expectations to capture more market share in a $40 billion industry [187] - **Focus on Core Business**: The company emphasizes that the core business, which is growing rapidly, should receive more attention than the smaller AI segment, which currently contributes less than 10% of revenues [188][190] Conclusion - Everpure is positioned strongly in the enterprise storage market with innovative technology, robust financial performance, and strategic acquisitions. The company is navigating industry challenges effectively while focusing on long-term growth and market share expansion.

Telix Pharmaceuticals (NasdaqGS:TLX) FY Conference February 26, 2026 04:40 PM ET Company ParticipantsChristian Behrenbruch - Managing Director and Group Chief Executive OfficerConference Call ParticipantsJeff Jones - Managing Director and Senior Analyst, BiotechnologyJeff JonesGood afternoon, everyone. Welcome back to the afternoon session of Oppenheimer's Annual Healthcare Conference. I'm Jeff Jones, one of the analysts on the biotech team here. I am delighted to be joined by Christian Behrenbruch, CEO of ...

The Brink's Company (NYSE:BCO) M&A announcement February 26, 2026 04:30 PM ET Company ParticipantsJesse Jenkins - VP of Investor RelationsKurt McMaken - CFOMark Eubanks - President and CEOTim Oliver - President and CEOTobey Sommer - Managing DirectorConference Call ParticipantsGeorge Tong - Managing Director and Senior Equity AnalystNone - AnalystOperatorGood day. Welcome to the Brink's acquisition of NCR Atleos. All participants will be in listen-only mode. Should you need assistance, please signal a confe ...

NCR Atleos (NYSE:NATL) M&A announcement February 26, 2026 04:30 PM ET Company ParticipantsJesse Jenkins - VP of Investor RelationsKurt McMaken - EVP and CFOMark Eubanks - President and CEOTim Oliver - President and CEOConference Call ParticipantsGeorge Tong - Managing Director and Senior Equity Research AnalystSam Kusswurm - AnalystToby Sommer - AnalystOperatorGood day, and welcome to the Brink's acquisition of NCR Atleos. All participants will be in listen-only mode. Should you need assistance, please sign ...

Veru (NasdaqCM:VERU) FY Conference February 26, 2026 03:20 PM ET Company ParticipantsMitch S. Steiner - Executive Chairman, President, and CEOConference Call ParticipantsLeland Gershell - Managing Director and Senior Biotechnology AnalystLeland GershellGreat! Thank you. Thanks for joining us here at Oppenheimer's 36th Annual Healthcare Life Sciences Conference. I'm Leland Gershell, one of the analysts with the Biotech Equity Research team at the firm. We're delighted to have with us as our next presenting c ...

Alumis (NasdaqGS:ALMS) FY Conference February 26, 2026 03:20 PM ET Company ParticipantsMartin Babler - President, Chief Executive Officer, and Chairman of the BoardConference Call ParticipantsJeff Jones - Managing Director and Senior Analyst, BiotechnologyJeff JonesAfternoon, everyone. Welcome back to Oppenheimer's Annual Healthcare Conference. I'm Jeff Jones. I'm one of the analysts here on the biotech team. I am delighted to be joined by Martin Babler and John Schroer, CEO and CFO of Alumis. Been a lot of ...

Summary of Voyager Therapeutics FY Conference Call Company Overview - **Company**: Voyager Therapeutics (NasdaqGS: VYGR) - **Industry**: Biotechnology, specifically focusing on gene therapy and treatments for neurodegenerative diseases, particularly Alzheimer's disease Key Points 1. Strategic Focus Areas - **Three Pillars of Value**: - **Tau Target**: Focus on tau as a target for Alzheimer's with two programs: VY7523 (anti-tau antibody) and VY-1706 (gene therapy) [2][3] - **Gene Therapy**: Plans to advance two gene therapy assets into clinical trials, one in partnership with Neurocrine and one wholly owned by Voyager [2] - **NeuroShuttle Platform**: Development of a platform to deliver various drugs across the blood-brain barrier [3] 2. Tau as a Target for Alzheimer's - **Importance of Tau**: The spread of tau in the brain correlates more closely with clinical decline in Alzheimer's than amyloid accumulation [6] - **Recent Developments**: Upcoming data from J&J and Biogen on tau-targeting therapies will provide further validation for tau as a target [5][6] - **Mixed Results from Competitors**: UCB's bepranemab showed some effect on tau spread but failed to meet primary clinical endpoints, indicating the complexity of targeting tau [8][9] 3. Clinical Development Insights - **VY7523**: Preliminary safety data shows a favorable profile, with a brain-to-plasma ratio of 0.3% and a half-life supporting monthly dosing [20] - **MAD Study Design**: The multiple ascending dose (MAD) study is designed to assess the effect on tau PET imaging, which is the key biomarker for evaluating the spread of pathological tau [21] - **Future Studies**: Plans to include tau PET imaging data in future studies and emphasize its importance over fluid-based biomarkers [24][25] 4. Gene Therapy Developments - **VY-1706**: Aiming for a 50%-70% reduction in tau mRNA/protein, with a focus on lower doses to enhance safety and reduce costs [31] - **FDA Interactions**: Productive discussions with the FDA regarding trial designs and plans to file an IND in Q2 2026 [33] 5. NeuroShuttle Platform - **Differentiation**: The ALPL shuttle shows longer half-life and no adverse effects on reticulocyte counts compared to transferrin receptor shuttles, making it a promising delivery method for various therapies [46] - **Therapeutic Modalities**: Exploring antibodies, peptides, and oligonucleotides for use with the NeuroShuttle platform [47] 6. Partnerships and Collaborations - **Neurocrine Partnership**: Progress on gene therapy programs, including FA and GBA1, with plans to enter the clinic this year [48] 7. Market Opportunities - **Alzheimer's Disease**: The potential for anti-tau therapies to be used in combination with anti-amyloid treatments, especially for patients who do not respond to the latter [41] - **Broader Applications**: Potential to address other tauopathies beyond Alzheimer's, expanding the market opportunities for Voyager's therapies [42] Additional Insights - **Clinical Predictions**: Anticipation that BIIB080 will show significant effects in clinical measures, which could influence Voyager's approach to VY-1706 [36] - **Patient Population**: Targeting early Alzheimer's patients for clinical trials, aligning with trends in the amyloid treatment landscape [26][27] This summary encapsulates the key discussions and insights from the Voyager Therapeutics FY Conference, highlighting the company's strategic focus, clinical developments, and market opportunities in the biotechnology sector.

Summary of Wave Life Sciences FY Conference Call Company Overview - **Company**: Wave Life Sciences (NasdaqGM: WVE) - **Focus**: RNA medicine and oligonucleotide optimization, with a strong emphasis on human clinical genetics and innovative chemistry [2][4] Key Points from 4Q Results - **Pipeline Development**: Significant advancements in the pipeline, particularly in obesity treatment with Inhibin E and RNA editing for alpha-1 antitrypsin deficiency [3][4] - **Clinical Data**: Upcoming clinical data expected for Inhibin E, including 240 mg six-month data and 400 mg three-month data [3][15] Obesity Treatment Insights - **Targeted Mechanism**: Inhibin E aims to address obesity by reducing visceral fat without significant loss of lean muscle mass, which is crucial for metabolic health [6][10][14] - **Clinical Feedback**: Key opinion leaders (KOLs) are interested in the mechanism that focuses on body composition rather than just weight loss [5][12] - **Initial Results**: At three months, the 240 mg dose showed nearly 10% reduction in visceral fat and a 0.9% increase in lean mass, indicating a favorable profile compared to existing therapies [13][19] Future Expectations - **Data Anticipation**: The 400 mg cohort data is expected to provide insights into dose dependency and time dependency of fat loss [17][19] - **Regulatory Considerations**: The company is confident in meeting FDA requirements for obesity drugs, focusing on both weight loss and body composition improvements [45][49] RNA Editing Program - **Alpha-1 Antitrypsin Deficiency**: The program aims to correct the deficiency by producing endogenous proteins, with potential for accelerated approval based on existing data [66][75] - **Regulatory Engagement**: Discussions with regulators are ongoing to establish a clear path for market entry and confirmatory studies [75][76] Strategic Insights - **Combination Therapies**: There is potential for Inhibin E to be used in combination with GLP-1 therapies, enhancing treatment options for obesity [52][54] - **Market Potential**: The company sees a significant opportunity in addressing the obesity epidemic, with a scalable and accessible treatment model [58][60] Innovations and Future Pipeline - **Bifunctional Modality**: The company is exploring bifunctional modalities that can target multiple pathways, enhancing therapeutic efficacy [78][80] - **Targeting Multiple Cell Types**: Future developments may include targeting both adipocytes and hepatocytes, broadening the therapeutic applications in cardiometabolic diseases [80] Conclusion - Wave Life Sciences is positioned at a critical juncture with innovative approaches to RNA medicine, particularly in obesity and genetic disorders. The upcoming clinical data and regulatory discussions will be pivotal in shaping the future of its therapies and market presence.

Summary of Kyntra Bio Conference Call Company Overview - **Company Name**: Kyntra Bio (formerly FibroGen) - **Focus**: Transitioned from fibrosis and collagen to oncology and rare diseases, reflecting a strategic transformation to leverage current momentum in these areas [1][2] Financial Highlights - **Sale of FibroGen China**: Completed sale to AstraZeneca for $220 million, which helped pay off senior secured debt and simplified capital structure [2][3] - **Cash Runway**: Extended into 2028, allowing for continued development of clinical programs [3] Clinical Development Programs FG-3246 and FG-3180 - **Indication**: Metastatic castration-resistant prostate cancer (mCRPC) - **Phase 2 Trial**: Initiated for FG-3246 (first-in-class targeting CD46) and FG-3180 (companion PET imaging agent) with interim results expected later this year [3][4] - **Clinical Responses**: Previous studies indicated meaningful clinical responses; 50%-70% of mCRPC patients express CD46 [10][53] Roxadustat - **Indication**: Anemia associated with lower-risk myelodysplastic syndromes (MDS) - **Commercial Opportunity**: Competing against luspatercept, which is projected to generate $2.3 billion in revenue by 2025, primarily in the U.S. [26] - **Regulatory Path**: Received orphan drug designation and is preparing for a phase 3 trial [5][31] Clinical Trial Insights - **Phase 1 Monotherapy Results**: Demonstrated a radiographic progression-free survival (RPFS) of 8.7 months in heavily pre-treated patients [13] - **Adverse Events**: Notable rates of neutropenia and peripheral neuropathy observed; strategies to mitigate these effects are being implemented [14][15][18] - **PET Imaging Correlation**: Evidence of correlation between CD46 expression and treatment response, which will be further evaluated in ongoing trials [20][21][54] Market Position and Strategy - **Unmet Need**: Significant unmet need in mCRPC, particularly for patients ineligible for or who have progressed on existing therapies [6][8] - **Targeted Approach**: Focus on non-PSMA approaches and the potential for combination therapies to enhance treatment efficacy [7][46] - **Patient Selection**: Utilizing PET imaging to select patients with high CD46 expression for better treatment outcomes [50][53] Future Outlook - **Upcoming Catalysts**: Anticipated interim results from ongoing trials and potential regulatory feedback on phase 3 protocols [5][6][32] - **Strategic Partnerships**: Engaging in discussions for potential business development opportunities while considering self-funding for trials [32] Conclusion Kyntra Bio is positioned to capitalize on its innovative oncology pipeline, particularly in mCRPC and MDS, with a strong focus on leveraging clinical data and strategic partnerships to enhance its market presence and patient outcomes [32][33]